Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + pegylated liposomal doxorubicin
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Paclitaxel + pegylated liposomal doxorubicin is a combination chemotherapy regimen consisting of two cytotoxic agents. Paclitaxel is a taxane that stabilizes microtubules and inhibits their disassembly, thereby blocking cell division and inducing apoptosis in cancer cells. Pegylated liposomal doxorubicin (PLD) is an anthracycline encapsulated in PEG-coated liposomes to enhance tumor delivery and reduce cardiotoxicity; it intercalates into DNA, inhibits topoisomerase II, and generates free radicals leading to DNA damage. This combination has been studied as first-line therapy for metastatic breast cancer[1] and advanced soft tissue sarcoma[2], showing efficacy with manageable toxicity profiles.
- Brand names
- DoxilTaxol
- Other names
- paclitaxel and pegylated liposomal doxorubicinpaclitaxel + PLDTaxol + Caelyx
02
Targets
TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on paclitaxel + pegylated liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + pegylated liposomal doxorubicin.